Sector Alpha Week of 2026-09-24
Not SEBI Registered !! Not Investment advice !!
Sector Alpha — machine-written from the numbers · Data as of 2026-09-24

USBC, Inc.

USBC
Technology · Scientific & Technical Instruments

USBC, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.

Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.

The price is between stages. Underneath, the last four quarters read mixed. What settles it: the next one or two quarters of delivery.

Price
$0.5
−56.9% 1Y
Revenue (Dec 25)
$0.0 B
Profit (Dec 25)
$−0.0 B
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

USBC, Inc. trades at $0.5, between stages. That is +13.6% against its own 200-day average. It sits at 24% of a 52-week range of $0 to $1. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 6 straight weeks.

Today the stock is between stages. At $0.5 it trades +13.6% versus its 200-day average and sits at 24% of its 52-week range ($0–$1).

Sep 26: $0.5 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 1-year window.
+13.6% versus the 200-day line, week — of stage —
Price50-day avg200-day avg
$3.6$2.7$1.8$0.9$0.1$$1$0Jul 25Oct 25Feb 26Jun 26Sep 26
$3.6$2.7$1.8$0.9$0.1$$1$0Jul 25Feb 26Sep 26
Beating or trailing, week by week since 2025 Each cell is one week from 2025 to now (64 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Jul 25Sep 26

Against the market, two honest reads. Cumulative: over the last 1.2 years the stock moved −85% while the S&P 500 moved +23% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 6 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.

P/E does not price USBC, Inc. — earnings are negative, so there is no multiple to rank against its own history. The revenue and margin lines below are where a turn, when it comes, would show first. A P/E returns here the first period the bottom line turns positive.

With earnings negative, P/E does not price — there is no multiple to rank against its own history. The revenue and margin lines below are where the turn, when it comes, will show first.

P/E
earnings negative
PEG
n/m
not derivable — 3-year earnings growth unavailable

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: No read

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read.

USBC, Inc. reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 4 quarters across 0 curves, on partial evidence.

Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. A missing point means that reading is not held for the quarter.
the trajectory the stage is read from
Revenue
−98.8%−99.4%−100.0%−100.6%−101.2%%−100%Jun 22Dec 22Sep 23Jun 24Dec 25
−98.8%−99.4%−100.0%−100.6%−101.2%%−100%Jun 22Sep 23Dec 25
ROE Annual readings — the quarterly balance-sheet pieces this curve needs are not held for this stock, so the returns read moves once a year and carries less weight in the call.
the return curve, annual readings
ROE
−5.6%−58%−110%−162%−214%%−20%FY22FY25
−5.6%−58%−110%−162%−214%%−20%FY22FY25

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

04 · 4-Factor Sector Score

4-Factor Sector Score

44.9/100 — rank 18 of 19 in Scientific & Technical Instruments · 20% evidence confidence · provisional, ranked below fully-evidenced peers

USBC, Inc. scores 44.9 out of 100 against the 19 companies it is compared with in Scientific & Technical Instruments, ranking 18. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 17.3 + 11.1 + 11.5 + 5 = 44.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

USBC, Inc. reported $0.0 B of revenue in the Dec 25 quarter. The last full year, FY25, came in at $0.0 B. The last four reported quarters add to $0.0 B. A multi-year compound rate is not shown because the annual history behind it is too short to compute one honestly.

FY25 revenue came in at $0.0 B (null on the year). The latest quarter (Dec 25) printed $0.0 B, null year on year.

FY25 revenue $0.0 B (null YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
Revenue
0.001−0.002−0.005−0.008−0.011$ B$0BFY21FY23FY25
0.001−0.002−0.005−0.008−0.011$ B$0BFY21FY23FY25
Dec 25: $0.0 B (null YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Revenue (quarterly)YoY growth
0.011−98.8%0.008−99.4%0.005−100.0%0.003−100.6%0.000−101.2%$ B%$0B−100%Jun 22Sep 23Dec 25
0.011−98.8%0.008−99.4%0.005−100.0%0.003−100.6%0.000−101.2%$ B%$0B−100%Jun 22Sep 23Dec 25
06 · Operating margin

Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

A clean operating margin is not in our numbers for USBC, Inc. — its accounts do not report the operating-profit line this section reads, which is common for lenders and holding companies. The sections above and below carry the readings this company's filings do support.

This company's accounts do not report the operating-profit line this section reads — common for lenders and holding companies classified outside the financial bucket. The revenue and net-profit sections are the cleaner reads for USBC, Inc..

Why: the numbers show the operating margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.

07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

USBC, Inc. posted a net loss of $0.03 B in the Dec 25 quarter. The full FY25 year was a loss of $0.02 B. The same quarter a year earlier lost $0.01 B. 3 of the last 12 reported quarters were loss-making.

Dec 25 profit was $−0.0 B, null year on year. On the full year, FY25 printed $−0.0 B (null).

FY25 profit $−0.0 B (null YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
Net profit
0.002−0.006−0.015−0.024−0.032$ B$0BFY21FY23FY25
0.002−0.006−0.015−0.024−0.032$ B$0BFY21FY23FY25
Dec 25: $−0.0 B (null YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)
0.002−0.006−0.015−0.024−0.032$ B$0BJun 22Sep 23Dec 25
0.002−0.006−0.015−0.024−0.032$ B$0BJun 22Sep 23Dec 25
08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

USBC, Inc.'s cash-flow history is too thin to judge how much reported profit converts into cash. In FY25 that was $−0.0 B of operating cash against $−0.0 B of profit. After null of capital spending, $−0.0 B was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.

FY25: operating cash of $−0.0 B against reported profit of $−0.0 B, leaving free cash of $−0.0 B after null of capital spending.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY25: CFO $−0.0 B vs profit $−0.0 B Operating cash flow and net profit by fiscal year, $ B; the line is free cash flow (CFO minus capital spending). 5-year window, annual resolution.
Operating cashNet profitFree cash
0.002−0.006−0.015−0.024−0.032$ B$0B$0B$0BFY21FY23FY25
0.002−0.006−0.015−0.024−0.032$ B$0B$0B$0BFY21FY23FY25
Dec 25: operating cash $0.0 B Operating cash per quarter, $ B (bars); conversion = operating cash as % of net profit (line, right). Last 12 quarters. Dashed line = 100%.
Operating cash (quarterly)100%
1.2101.2%0.6100.6%0.0100.0%−0.699.4%−1.298.8%$ B%$0BMar 23Jun 24Dec 25
1.2101.2%0.6100.6%0.0100.0%−0.699.4%−1.298.8%$ B%$0BMar 23Jun 24Dec 25

Router verdict: the visible cash user is investment — the next section checks what the spending is buying.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

USBC, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Nothing is estimated in place of the missing day-counts, so no cash-cycle chart is drawn.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

On the investment side: capital spending of $0.0 B over the last 3 fiscal years.

FY24: capex $0.0 B Capital spending per fiscal year, $ B (bars).
steady investment
Capex
1.20.60.0−0.6−1.2$ B$0BFY21FY22FY24
1.20.60.0−0.6−1.2$ B$0BFY21FY22FY24
Sep 24: capex $0.0 B in the quarter Capital spending per quarter, $ B (bars, left); free cash flow, $ B (line, right). Last 12 quarters.
Capex (quarterly)Free cash
1.21.20.60.60.00.0−0.6−0.6−1.2−1.2$ B$ B$0B$0BDec 21Mar 23Sep 24
1.21.20.60.60.00.0−0.6−0.6−1.2−1.2$ B$ B$0B$0BDec 21Mar 23Sep 24

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

10 · Return on equity

Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.

USBC, Inc. earns a ROE of −20% in FY25. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 200.0% net margin on −1.00× asset turns.

FY25 ROE is −20%.

Why the return is what it is — the wiring (FY22): 200.0% net margin × −1.00× asset turns × 1.00× balance-sheet leverage ≈ −200.0% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.

FY25: ROE −20% Return on equity by fiscal year, % (line). 2-year window, dips included. Dashed line = the 11.7% cost of capital used on this page.
the full ladder
ROEWACC
29%−33%−94%−156%−217%%−20%FY22FY25
29%−33%−94%−156%−217%%−20%FY22FY25
Dec 25: ROE −70.7% (TTM) Trailing-twelve-month ROE, per quarter, %. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROE (TTM)
632%287%−59%−405%−751%%−70.7%Mar 23Jun 24Dec 25
632%287%−59%−405%−751%%−70.7%Mar 23Jun 24Dec 25
11 · Dividend

Dividend

USBC, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.

USBC, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.

12 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

USBC, Inc. carries total debt of $0.0 B against shareholder equity of $0.1 B as of Dec 25, a debt-to-equity of 0.00 — effectively unlevered. The returns elsewhere on this page are therefore earned rather than borrowed.

Dec 25: total debt of $0.0 B against shareholder equity of $0.1 B — a debt-to-equity of 0.00. The returns on this page are earned, not borrowed.

FY25: debt $0.0 B at 0.00× equity Total debt by fiscal year, $ B (bars); debt-to-equity, × (line). 5-year window.
Total debtDebt-to-equity
1.21.2×0.60.6×0.00.0×−0.6−0.6×−1.2−1.2×$ B×$0B0.00×FY21FY23FY25
1.21.2×0.60.6×0.00.0×−0.6−0.6×−1.2−1.2×$ B×$0B0.00×FY21FY23FY25
Dec 25: debt $0.0 B, debt-to-equity 0.00 Total debt per quarter, $ B (bars); debt-to-equity, × (line). Last 12 quarters.
Total debt (quarterly)Debt-to-equity
1.21.2×0.60.6×0.00.0×−0.6−0.6×−1.2−1.2×$ B×$0B0.00×Mar 23Jun 24Dec 25
1.21.2×0.60.6×0.00.0×−0.6−0.6×−1.2−1.2×$ B×$0B0.00×Mar 23Jun 24Dec 25
13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

3.4% of USBC, Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 1.5 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

The latest reading: 3.4% of the float is sold short, and at typical trading volumes it would take about 1.5 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Short interest
3.4%
of the tradable float
Days to cover
1.5
at typical volumes

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

USBC, Inc.: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

15 · Related companies · Scientific & Technical Instruments
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Garmin Ltd.GRMN 72.4/100Favorable setup81% evidence BREAKING OUT 23.3/35 Revenue 13.5% · PAT 19.7% · OPM change 4.4 pp 83% evidence 17.0/25 ROCE 6.9% · OPM 30.4% 76% evidence 13.4/20 P/E 24× · PEG 1.22 65% evidence 18.7/20 RS sector 9.5% · RS bench 11.1% · 1Y 19.6%9 of 12 weeks ahead 100% evidence
Exact sum: 23.3 + 17 + 13.4 + 18.7 = 72.4 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
2Keysight Technologies, Inc.KEYS 70.4/100Favorable setup81% evidence TURNING 28.2/35 Revenue 19.2% · PAT 44.6% · OPM change 7.9 pp 83% evidence 15.0/25 ROCE 4.5% · OPM 23.7% 76% evidence 11.0/20 P/E 57.6× · PEG 1.35 65% evidence 16.2/20 RS sector 19.1% · RS bench 19.7% · 1Y 103.9%0 of 12 weeks ahead 100% evidence
Exact sum: 28.2 + 15 + 11 + 16.2 = 70.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3Cognex CorporationCGNX 57.6/100Thin evidence · provisional56% evidence ASLEEP 22.1/35 Revenue — · PAT — · OPM change 4.9 pp 39% evidence 14.9/25 ROCE 3.4% · OPM 22.3% 76% evidence 9.4/20 P/E 58.5× · PEG — 15% evidence 11.2/20 RS sector 2% · RS bench 2.8% · 1Y 27.1%4 of 12 weeks ahead 100% evidence
Exact sum: 22.1 + 14.9 + 9.4 + 11.2 = 57.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
4Coherent Corp.COHR 57.1/100Mixed-positive evidence71% evidence ASLEEP 28.5/35 Revenue 22.5% · PAT 100% · OPM change 12 pp 83% evidence 6.9/25 ROCE 1.8% · OPM 12.4% 76% evidence 8.7/20 P/E 95.7× · PEG — 15% evidence 13.0/20 RS sector 9.1% · RS bench 9.1% · 1Y 181%1 of 12 weeks ahead 100% evidence
Exact sum: 28.5 + 6.9 + 8.7 + 13 = 57.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5MKS Inc.MKSI 52.6/100Mixed-positive evidence66% evidence ASLEEP 20.1/35 Revenue 11.5% · PAT 43.4% · OPM change 1.9 pp 53% evidence 10.2/25 ROCE 2.1% · OPM 13.8% 57% evidence 13.6/20 P/E 48.1× · PEG 1.13 65% evidence 8.7/20 RS sector -0.3% · RS bench -0.1% · 1Y 115.7%3 of 12 weeks ahead 100% evidence
Exact sum: 20.1 + 10.2 + 13.6 + 8.7 = 52.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6Mesa Laboratories, Inc.MLAB 51.6/100Thin evidence · provisional51% evidence BREAKING OUT 16.1/35 Revenue 3.7% · PAT — · OPM change 1.9 pp 40% evidence 6.3/25 ROCE 0.9% · OPM 4.3% 57% evidence 9.2/20 P/E 73.1× · PEG — 15% evidence 20.0/20 RS sector 30.3% · RS bench 31.8% · 1Y 106.2%6 of 12 weeks ahead 100% evidence
Exact sum: 16.1 + 6.3 + 9.2 + 20 = 51.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
7Ituran Location and Control Ltd.ITRN 50.6/100Thin evidence · provisional60% evidence ASLEEP 15.9/35 Revenue 11.3% · PAT 6.9% · OPM change -0.1 pp 53% evidence 15.9/25 ROCE 8.6% · OPM 21.5% 57% evidence 10.3/20 P/E 16.2× · PEG 1.8 65% evidence 8.5/20 RS sector -3.4% · RS bench -2.5% · 1Y 49.3%0 of 12 weeks ahead 70% evidence
Exact sum: 15.9 + 15.9 + 10.3 + 8.5 = 50.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
8Novanta Inc.NOVT 49.1/100Thin evidence · provisional56% evidence ASLEEP 21.4/35 Revenue — · PAT — · OPM change 4.5 pp 39% evidence 9.8/25 ROCE 2% · OPM 10.7% 76% evidence 8.9/20 P/E 84.8× · PEG — 15% evidence 9.0/20 RS sector -1.5% · RS bench -0.3% · 1Y 43%4 of 12 weeks ahead 100% evidence
Exact sum: 21.4 + 9.8 + 8.9 + 9 = 49.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
9Vontier CorporationVNT 48.4/100Thin evidence · provisional56% evidence FADING 16.1/35 Revenue — · PAT — · OPM change 0.4 pp 39% evidence 14.7/25 ROCE 3.6% · OPM 18% 76% evidence 11.3/20 P/E 12.5× · PEG — 15% evidence 6.3/20 RS sector -20% · RS bench -18.2% · 1Y -25.7%6 of 12 weeks ahead 100% evidence
Exact sum: 16.1 + 14.7 + 11.3 + 6.3 = 48.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
10Trimble Inc.TRMB 47.7/100Thin evidence · provisional56% evidence BREAKING OUT 20.1/35 Revenue — · PAT — · OPM change 3.7 pp 39% evidence 10.5/25 ROCE 1.9% · OPM 15.3% 76% evidence 10.4/20 P/E 33.1× · PEG — 15% evidence 6.7/20 RS sector -20.2% · RS bench -18.1% · 1Y -27%5 of 12 weeks ahead 100% evidence
Exact sum: 20.1 + 10.5 + 10.4 + 6.7 = 47.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
11Sensata Technologies Holding plcST 45.9/100Thin evidence · provisional56% evidence ASLEEP 18.2/35 Revenue — · PAT — · OPM change 1.7 pp 39% evidence 11.0/25 ROCE 2.7% · OPM 15.1% 76% evidence 9.0/20 P/E 79.6× · PEG — 15% evidence 7.7/20 RS sector -2.6% · RS bench -1.6% · 1Y 37.5%4 of 12 weeks ahead 100% evidence
Exact sum: 18.2 + 11 + 9 + 7.7 = 45.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
12Teledyne Technologies IncorporatedTDY 44.5/100Mixed-negative evidence81% evidence ASLEEP 15.2/35 Revenue 7.9% · PAT 13.5% · OPM change 1.6 pp 83% evidence 13.1/25 ROCE 2.5% · OPM 20% 76% evidence 8.2/20 P/E 30.1× · PEG 2.15 65% evidence 8.0/20 RS sector -6.2% · RS bench -4.9% · 1Y 7.6%2 of 12 weeks ahead 100% evidence
Exact sum: 15.2 + 13.1 + 8.2 + 8 = 44.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
13Badger Meter, Inc.BMI 44.4/100Thin evidence · provisional56% evidence ASLEEP 13.7/35 Revenue — · PAT — · OPM change -4.8 pp 39% evidence 15.4/25 ROCE 4.8% · OPM 17.4% 76% evidence 10.1/20 P/E 34.7× · PEG — 15% evidence 5.2/20 RS sector -21.3% · RS bench -19.3% · 1Y -24.6%5 of 12 weeks ahead 100% evidence
Exact sum: 13.7 + 15.4 + 10.1 + 5.2 = 44.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
14Itron, Inc.ITRI 43.0/100Thin evidence · provisional56% evidence FADING 14.6/35 Revenue — · PAT — · OPM change -1.1 pp 39% evidence 9.6/25 ROCE 2.5% · OPM 11.5% 76% evidence 11.1/20 P/E 14.4× · PEG — 15% evidence 7.7/20 RS sector -14% · RS bench -12.1% · 1Y -26.3%8 of 12 weeks ahead 100% evidence
Exact sum: 14.6 + 9.6 + 11.1 + 7.7 = 43 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
15ESCO Technologies Inc.ESE 40.1/100Mixed-negative evidence66% evidence ASLEEP 18.0/35 Revenue 30.7% · PAT 16.7% · OPM change -0.5 pp 53% evidence 13.1/25 ROCE 2.8% · OPM 15.5% 57% evidence 4.7/20 P/E 54.2× · PEG 6 65% evidence 4.3/20 RS sector -8.4% · RS bench -7.6% · 1Y 29.8%0 of 12 weeks ahead 100% evidence
Exact sum: 18 + 13.1 + 4.7 + 4.3 = 40.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
16Fortive CorporationFTV 39.2/100Thin evidence · provisional53% evidence ASLEEP 15.8/35 Revenue — · PAT — · OPM change -5.6 pp 32% evidence 8.2/25 ROCE 1.7% · OPM 9% 76% evidence 10.3/20 P/E 33.3× · PEG — 15% evidence 4.9/20 RS sector -9.9% · RS bench -8.5% · 1Y 15.9%0 of 12 weeks ahead 100% evidence
Exact sum: 15.8 + 8.2 + 10.3 + 4.9 = 39.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
17Vishay Precision Group, Inc.VPG 37.6/100Thin evidence · provisional56% evidence ASLEEP 13.3/35 Revenue — · PAT — · OPM change -3.2 pp 39% evidence 4.5/25 ROCE 0.1% · OPM 0.4% 76% evidence 8.5/20 P/E 99.5× · PEG — 15% evidence 11.3/20 RS sector 3.7% · RS bench 3.3% · 1Y 116.9%4 of 12 weeks ahead 100% evidence
Exact sum: 13.3 + 4.5 + 8.5 + 11.3 = 37.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
18USBC, Inc.this pageUSBC 44.9/100Thin evidence · provisional20% evidence BREAKING OUT 17.3/35 Revenue — · PAT — · OPM change — 2% evidence 11.1/25 ROCE — · OPM — 11% evidence 11.5/20 P/E 0.9× · PEG — 15% evidence 5.0/20 RS sector -15.8% · RS bench -12.5% · 1Y -56.9%5 of 12 weeks ahead 70% evidence
Exact sum: 17.3 + 11.1 + 11.5 + 5 = 44.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
19MicroVision, Inc.MVIS 30.4/100Thin evidence · provisional39% evidence 10.6/35 Revenue -80% · PAT — · OPM change -129 pp 40% evidence 6.8/25 ROCE -35.2% · OPM — 46% evidence 10.0/20 P/E — · PEG — 0% evidence 3.0/20 RS sector -68.3% · RS bench -66.3% · 1Y -76.9%0 of 3 weeks ahead to 2026-07-24 70% evidence
Exact sum: 10.6 + 6.8 + 10 + 3 = 30.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is USBC, Inc.'s stock price today?

USBC, Inc. trades at $0.5, −56.9% over the past year. The company is valued at $0.0 B. The stock sits at 24% of its 52-week range of $0–$1, +13.6% versus its 200-day average. Against the S&P 500 it has been ahead on a trailing-13-week view for 6 weeks. — as of 24 September 2026.

What were USBC, Inc.'s latest quarterly results?

USBC, Inc. reported revenue of $0.0 B and a net loss of $0.0 B for the Dec 25 quarter. Earnings per share were $−0.07. — as of 24 September 2026.

What is USBC, Inc.'s revenue?

USBC, Inc. reported revenue of $0.0 B in the Dec 25 quarter. For the full FY25 fiscal year, revenue was $0.0 B. — as of 24 September 2026.

What is USBC, Inc.'s profit?

USBC, Inc. earned $−0.0 B of net profit in the Dec 25 quarter. Full-year FY25 profit was $−0.0 B. — as of 24 September 2026.

What is USBC, Inc.'s market cap?

USBC, Inc.'s market capitalisation is $0.0 B at a stock price of $0.5. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 September 2026.

Does USBC, Inc. pay a dividend?

No — USBC, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 24 September 2026.

How is USBC, Inc. performing?

USBC, Inc.'s latest readings are below. Against the S&P 500 it has been ahead on a trailing-13-week view for 6 weeks. This describes what the data did, not a rating. — as of 24 September 2026.

Is USBC, Inc. beating the market?

On recent form, yes — USBC, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 6 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.2 years the stock moved −85% against the S&P 500's +23% — behind the index over the full window. — as of 24 September 2026.

Will USBC, Inc.'s stock price go up?

This page publishes no price forecast for USBC, Inc. What it measures instead: the stock price is $0.5. Direction is not something this site claims to know. — as of 24 September 2026.

Is the market betting against USBC, Inc.?

Somewhat — short interest is 3.4% of USBC, Inc.'s tradable float, about 1.5 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 24 September 2026.

Does USBC, Inc. have too much debt?

It is moderate — USBC, Inc.'s debt-to-equity is 0.33. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 24 September 2026.

What is USBC, Inc.'s capex?

USBC, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY24 alone that was $0.0 B. — as of 24 September 2026.

What is USBC, Inc.'s cash flow?

USBC, Inc. consumed $0.0 B of operating cash in FY25 — cash flowed out rather than in (free cash flow: $−0.0 B). Reported profit that year was $−0.0 B, so operating cash ran ahead of profit. — as of 24 September 2026.

What could break the USBC, Inc. story?

Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 September 2026.

Is USBC, Inc. a stock worth studying right now?

This is not investment advice. The machine read: USBC, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 September 2026.

Sector Alpha — machine-written from the numbers · Data as of 2026-09-24. Every chart on this page is drawn by deterministic code from the raw series — no forecasts, no price opinions, and nothing here is investment advice.

Not SEBI Registered !! Not Investment advice !!

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI